What is a stock summary page? Click here for an overview.
Business Description
Agile Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00847L1008
Compare
Compare
Traded in other countries / regions
AGRX.USA0AL.Germany Index Membership
Russell 2000 IPO Date
2014-05-23Description
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.86 | |||||
| Equity-to-Asset | -1.46 | |||||
| Debt-to-Equity | -0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -43.23 | |||||
| Beneish M-Score | -6.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.1 | |||||
| 3-Year EBITDA Growth Rate | 82.8 | |||||
| 3-Year EPS without NRI Growth Rate | 79.9 | |||||
| 3-Year FCF Growth Rate | 84.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 50.88 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 90.3 | |||||
| 9-Day RSI | 84.13 | |||||
| 14-Day RSI | 82.95 | |||||
| 6-1 Month Momentum % | 79.41 | |||||
| 12-1 Month Momentum % | -29.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.55 | |||||
| Quick Ratio | 0.33 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 160.32 | |||||
| Days Sales Outstanding | 70.19 | |||||
| Days Payable | 481.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -306.9 | |||||
| Shareholder Yield % | -53.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.63 | |||||
| Operating Margin % | -62.85 | |||||
| Net Margin % | -73.52 | |||||
| FCF Margin % | -7.91 | |||||
| ROA % | -129.36 | |||||
| ROIC % | -361.7 | |||||
| 3-Year ROIIC % | -201.4 | |||||
| ROC (Joel Greenblatt) % | -3098.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.27 | |||||
| EV-to-EBIT | -0.52 | |||||
| EV-to-EBITDA | -0.54 | |||||
| EV-to-Revenue | 0.36 | |||||
| EV-to-Forward-Revenue | 0.07 | |||||
| EV-to-FCF | -4.61 | |||||
| Price-to-GF-Value | 1.86 | |||||
| Earnings Yield (Greenblatt) % | -192.31 | |||||
| FCF Yield % | -16.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AGRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agile Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 21.568 | ||
| EPS (TTM) ($) | -3.13 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.64 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 316.38 | ||
| 14-Day RSI | 82.95 | ||
| 14-Day ATR ($) | 0.022728 | ||
| 20-Day SMA ($) | 1.468115 | ||
| 12-1 Month Momentum % | -29.61 | ||
| 52-Week Range ($) | 0.2 - 2.63 | ||
| Shares Outstanding (Mil) | 6.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agile Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agile Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agile Therapeutics Inc Frequently Asked Questions
What is Agile Therapeutics Inc(AGRX)'s stock price today?
The current price of AGRX is $1.51. The 52 week high of AGRX is $2.63 and 52 week low is $0.20.
When is next earnings date of Agile Therapeutics Inc(AGRX)?
The next earnings date of Agile Therapeutics Inc(AGRX) is 2025-03-28 Est..
Does Agile Therapeutics Inc(AGRX) pay dividends? If so, how much?
Agile Therapeutics Inc(AGRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers